DOCSLIB.ORG

Caring and Curing Annual Report 2003 UG E RZ Innen 27.2.2004 10:32 Uhr Seite 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

UG_e_RZ_neu_Aussen 27.2.2004 10:36 Uhr Seite 1 www.novartis.com Caring and Curing Novartis Annual Report 2003 Annual Report 2003 UG_e_RZ_innen 27.2.2004 10:32 Uhr Seite 1 Novartis pharmaceutical production, Stein, Switzerland Novartis pharmaceutical production, Changping, Beijing, China Contents Overview 2 Financial Highlights 3 News in 2003 Letter from Daniel Vasella 5 The New Number Five in Pharmaceuticals Division and Business Units 9 Pharmaceuticals Giving Thalassemia Patients a Choice Discovering Pharmaceuticals Reliably and Predictably The Long Road to Blood-Pressure Control Treating Breast Cancer Will Never Be the Same Epilepsy - Putting Children First A New Frontier in the Fight Against Severe Allergic Asthma Two Decades of Leadership in Transplantation Hearing the Patient, Healing the Patient - Irritable Bowel Syndrome The Right Note: Saving a Singer’s Sight 32 Consumer Health Sandoz - Building a World Leader in Generics OTC - The Value of Global Brands Animal Health - Up and Running, Despite Arthritis Medical Nutrition - A New Relevance for Cancer Patients Infant & Baby - Alerting Parents to the Dangers of Childhood Obesity CIBA Vision - Innovation in Focus Corporate Citizenship 45 Active Societal Engagement Health, Safety and Environment 57 Turning Strong Commitment Into Firm Actions Human Resources 69 Fulfilling Career Aims Corporate Governance Section 77 Corporate Governance 90 Board of Directors 94 Executive Committee 96 Business Unit Heads Financial Report 99 Operating and Financial Review 111 Equity Strategy and Share Information 118 Group Consolidated Financial Statements and Notes 152 Principal Companies 154 Reconciliation to US GAAP 166 Financial Statements of Novartis AG Due Dates for Reporting in 2004 172 Contacts 173 Novartis Group Front cover: Mother and her sick child, Mumbai, India 1 Financial Highlights Sales USD millions Free cash flow USD millions 2003 24 864 2003 3 628 2002 20 877 2002 2 958 2001 18 762 2001 2 453 Operating income USD millions Research and development USD millions 2003 5 889 2003 3 756 2002 5 092 2002 2 843 2001 4 325 2001 2 528 Net income USD millions Employees at year end 2003 5 016 2003 78 541 2002 4 725 2002 72 877 2001 3 836 2001 71 116 Key ratios Share information 2003 2002 2003 2002 Return on sales (%) 23.7 24.4 Average number Return on average equity (%) 17.1 17.7 of shares outstanding 2 473 522 565 2 515 311685 Group research and development as % of sales 15.1 13.6 Earnings per share (USD) 2.03 1.88 Debt/equity ratio 0.20:1 0.20:1 Operating cash flow per share (USD) 2.68 2.08 Current ratio 2.4:1 2.5:1 American Depositary Share (ADS) price at end of year (USD) 45.89 36.73 Share price at end of year (CHF) 56.15 50.45 Dividend per share1 (CHF) 1.00 0.95 Pay-out ratio based on outstanding shares (%) 39 36 1 2003: Proposal to the Annual General Shareholder Meeting Sales by division Operating income by division Sales by region Pharmaceuticals 64% Pharmaceuticals 77% 41% US 36% Consumer Health 23% Consumer Health 8% Canada and Latin America 35% Europe 16% Africa/Asia/Australia 2 Novartis Group News in 2003 Group sales Strong volume growth in Pharmaceuticals and Sandoz: Group sales up 19% in USD (+11% in local currencies); Novartis is one of the fastest growing top-ten pharmaceutical companies Pharmaceuticals Pharmaceuticals steadily gaining market share in all major markets, with sales growth of 18% in USD, driven by the Cardiovascular and Oncology franchises Consumer Health Consumer Health ongoing sales up 24% driven by 60% sales growth at Sandoz New drugs With seven major approvals and 79 projects in clinical development and registration Novartis has one of the leading pipelines in the industry Operating income Double-digit (16%) rise in full-year operating income is driven by volume expansion, product mix enhance- ments and productivity gains Net income Net income is up 6% to a new record level of USD 5.0 billion, lifting earnings per share by 8% Dividend Based on solid performance, a dividend increase of 5% to CHF 1.00 per share will be proposed to shareholders Novartis Group 3 Our Healthcare Development Center, Thane, India Letter from Daniel Vasella Daniel Vasella, MD Kantonsspital, Basel, Switzerland Dear Shareowner, It gives me great pleasure to be able to present record results again. Today, Novartis is one of the fastest grow- ing global pharmaceutical companies. Thus, we have overtaken competitors and are now in fifth position in the Global Pharmaceuticals sector. At the same time, we have gained market segment share in all of our other busi- nesses. Let me summarize the key results in 2003: • Increase in group sales of 19% to USD 24.9 billion (+ 11% in local currencies) • Expansion of operating income to USD 5.9 billion (+16%), of net income to USD 5.0 billion (+6%) and of earnings per share by 8% to USD 2.03 • Growth of free cash flow by 23% to USD 3.6 billion • Pharmaceutical sales climbed 18% with the especially successful enlargement of our product line in Oncology (+36%) and Cardiovascular medicine (+36%), combined with a further rejuvenation of our product portfolio • Dynamic growth of our Consumer Health business (+24%) and particularly of our Generics business, Sandoz (+60%) • Expansion of our development pipeline to 79 projects, of which 34 are in late stage development or registration • Extension of our access to medicine programs for uninsured and indigent patients suffering from leprosy, malaria, tuberculosis, chronic myeloid leukemia and other diseases. We attribute our success to our clear focus on sustain- able growth, our corresponding, consistently innovation- oriented strategy, and the capabilities and commitment of our associates. Accordingly, we see our investments in Research and Development as being of primary impor- tance. Last year we increased our investment in Research and Development by 32%. In Pharmaceuticals alone, we invested more than USD 3 billion in 2003 to discover and develop innovative medicines, and to improve treatments for patients. The first phase in the buildup of our new research center in Cambridge, Massachusetts was success- fully completed. Nearly 400 scientists are already working in the new laboratories. In 2004, we will continue the expan- sion. This demands continued over-proportional invest- ments that will yield mid- to long-term returns. Novartis Group 5 Our development pipeline is among the best in the world, Elidel, our eczema treatment; as well as to the attractive based on quality and productivity. Most promising are our sales of Zelnorm/Zelmac, our irritable bowel treatment, to novel compounds for patients with diabetes, hypertension, name just some of our most important products. cancer and osteoporosis, and for transplantation medicine which will, if successful, significantly improve treatments The dynamic growth of our Generics business is primarily and thus have an attractive commercial potential. based on the success of AmoxC, loratadine and omeprazole in the US market. The development of activities at Lek, a In 2003, we received first major market approvals for generics company we acquired in 2002, also exceeded Certican and Myfortic for use in transplantation medicine, expectations. Stalevo for the treatment of Parkinson’s disease and Xolair for allergic asthma therapy in the US. Furthermore, In light of the increasing age of our society, and the asso- Prexige, a new treatment for pain and osteoarthritis, was ciated rise in healthcare expenditure, generics will play an approved in the UK. Its approval in the US is as yet uncer- even more important role as a cost effective therapeutic tain, pending results of additional trials. option. These cost savings can and should be used to provide patients with innovative, patent-protected medi- To complement our own research activities, we have estab- cines that have improved efficacy and safety profiles. lished several new collaborations with universities and biotechnology companies. The acquisition of 51% of the Unavoidably, governments, insurers and employers will capital stock of Idenix Pharmaceuticals Inc., a biotech- continue to put pressure on the price of pharmaceuticals, nology company based in Boston, Massachusetts, offers despite the fact that the overall cost of drug therapies us rapid entry into anti-viral research, and access to amounts to less than 20% of all healthcare-related costs development compounds for the treatment of hepatitis B in most countries. Also, medicines not only extend and C. Additionally, we acquired the commercial rights for patients’ life expectancy, but also improve their quality of Lucentis outside the US, Canada and Mexico. In combi- life and reduce their lost working hours and absence nation with our product Visudyne, this drug may improve from work due to illness. the treatment options in age-related macular degeneration, a frequent cause of blindness in adults. We also obtained Increasingly, health is regarded as a fundamental right. rights to a promising cancer drug, Gimatecan, from Sigma The introduction of prescription drug coverage into the Tau and the drug Enablex/Emselex for the treatment of US Medicare insurance system for senior citizens must urinary incontinence from Pfizer. also be seen from this perspective. Our market position improved in most countries, most The enlargement of the EU from 15 to 25 member states notably in the US. This we achieved thanks to the success will not only improve the standard of living in the new of our blood pressure-regulating medicines Diovan and member states, but also lead to demands for better Lotrel; our cancer drugs Gleevec/Glivec and Zometa; health-related products and services. A similar trend can 6 Novartis Group be observed in countries with rapidly growing Gross owners, to assess the current situation, risks and oppor- National Product (GNP), such as China and India. In each tunities of your company.
Recommended publications
  • 100 GREAT STREET PHOTOGRAPHS David Gibson PRESTEL Munich • London • New York

    100 GREAT STREET PHOTOGRAPHS David Gibson PRESTEL Munich • London • New York

    100SP-24_rl.indd 2 24.02.17 16:36 100 GREAT STREET PHOTOGRAPHS David Gibson PRESTEL Munich • London • New York 100SP-24_rl.indd 3 24.02.17 16:36 © 2017 Prestel Verlag, Munich · Editorial direction: Lincoln Dexter London · New York, a member of Copy-editing: Malcolm Imrie Verlagsgruppe Random House Design and layout: Hoop Design GmbH, Neumarkter Straße 28, Production management: Friederike 81673 Munich Schirge Separations: Reproline Mediateam, © for the texts, David Gibson, 2017 Munich © for the works reproduced is held Printing and binding: DZS Grafik, by the individual photographers, their d.o.o., Ljubljana heirs or assigns, with the exception Paper: Profisilk of the following images: p. 31, © Alex Webb/Magnum Photos; p. 35, © Martin Parr/Magnum Photos; p. 61, © Harry Gruyaert/ Magnum Photos; p.91, © Nikos Verlagsgruppe Random House FSC® Economopoulos/Magnum Photos; N001967 and p. 137, © Trent Parke/Magnum Photos ISBN 978-3-7913-8313-2 In respect to links in the book the www.prestel.com Publisher expressly notes that no illegal content was discernible on the linked sites at the time the links were created. The Publisher has no influence at all over the current and future design, content or authorship of the linked sites. For this reason the Publisher expressly disassociates itself from all content on linked sites that has been altered since the link was created and assumes no liability for such content. Front cover: detail of photograph by Marcin Ryczek, see pp. 161 Frontispiece: detail of photograph by Dan Szpara, Shinjuku, Tokyo, July 2016, see p. 181 Back cover: detail of photograph by Shin Noguchi, see pp.
  • A Rapid Evidence Assessment: Does Marketing of Commercially Available

    A Rapid Evidence Assessment: Does Marketing of Commercially Available

    A rapid evidence assessment Does marketing of commercially available complementary foods affect infant and young child feeding? Commissioned by the World Health Organization May 2015 Authors Dr Julie P Smith 1 Dr Ginny M Sargent 2 Dr Kaye Mehta 3 Dr Jennifer James 4 Dr Nina Berry 5 Colleen Koh 7 Libby Salmon 1 Miranda Blake 6 1. Regulatory Institutions Network, The Australian National University, Canberra ACT 2601 Australia www.anu.edu.au CRICOS Provider No. 00120C. 2. National Centre for Epidemiology and Population Health, Research School of Population Health, The Australian National University. 3. Nutrition & Dietetics, Flinders University, Adelaide, South Australia. 4. RMIT University, Bundoora, Victoria. 5. Sydney School of Public Health, University of Sydney NSW 2006. 6. School of Public Health and Preventative Medicine, Monash University, Australia. 7. Epidemiology Branch, Western Australia Department of Health, Western Australia Study expert panel Alessandro Iellamo, Independent Consultant, member of WHO STAG, formerly WHO WPRO. Dr Adriano Cattaneo, Health Services Research and International Health, Institute for Maternal and Child Health, Via dell'Istria 65/1, Trieste 34137, Italy. Professor Gerard Hastings, OBE, Professor of Social Marketing, University of Stirling and the Open University and L’École des Hautes Etudes en Santé Publique. Dr Peter Mansfield, OAM, Visiting Research Fellow, Discipline of General Practice, University of Adelaide. Corresponding author Dr Julie P Smith, Ph. +61 4 16099630, Email: [email protected] Rapid review on the effects of marketing of complementary foods page ii Acknowledgments The assistance of Dr Lucinda Bell, Nutrition & Dietetics, Flinders University, Ms Claire Caldwell and Dr Phil Baker, The Australian National University, in the preparation of this study is gratefully acknowledged.
  • (DAVID SEYMOUR) Woman in the Crowd CAROLE NAGGAR 24 1936

    (DAVID SEYMOUR) Woman in the Crowd CAROLE NAGGAR 24 1936

    INHALT Vorwort KRISTEN LUBBEN 8 1930-49 1933 HENRI CARTIER-BRESSON Sevilla 18 1936 CHIM (DAVID SEYMOUR) Woman in the Crowd CAROLE NAGGAR 24 1936 HERBERT LIST Man and Doq PEER-OLAF RICHTER 26 1938 ROBERT CAPA The Battie of Rio Segre CYNTHIA YOUNG 28 1940 WERNER BISCHOF Mountains MARCO BISCHOF 36 1940 GEORGE RODGER The Blitz 40 1941 GEORGE RODGER Western Desert 46 1944 ROBERT CAPA D-Day CYNTHIA YOUNG 50 1945 ROBERT CAPA Leipzig CYNTHIA YOUNG 56 1946 HERBERT LIST Plaster Casts at the Academy PEER-OLAF RICHTER 60 1948 CHIM (DAVID SEYMOUR) Girls Sewing CAROLE NAGGAR 62 1948 PHILIPPE HALSMAN Dah'Atomicus 64 1950-59 1951 WERNER BISCHOF Courtyard of the Meiji Temple MARCO BISCHOF 68 1953 ELLIOTT ERWITT Mother and Child 70 1953 MARC RIBOUD Eiffel Tower Painter 74 1955 CORNELL CAPA Fall of Peron CYNTHIA YOUNG 78 1956 ERICH LESSING Budapest 82 1957 BURT GLINN Little Rock, Arkansas 88 1957 INGE MORATH A Llama in Times Square JOHN JACOB 92 1959 EVE ARNOLD Joan Crawford 96 1959 ELLIOTT ERWITT Kitchen Debate 100 1959 BURT GLINN Fidel Castro 104 1959 MARILYN SILVERSTONE The Dalai Lama JAMES A.FOX 108 1960-69 1960 RENE BURRI Ministry of Health 114 1960 INGE MORATH Refugee Camps JOHN JACOB 118 1961 EVE ARNOLD Malcolm X 122 1961 CORNELL CAPA The White House CYNTHIA YOUNG 124 1961 BRUCE DAVIDSON Civil Rights Movement 130 1961 PHILIP JONES GRIFFITHS Boy Destroying Piano BRIGITTE LARDINOIS 138 1962 CONSTANTINE MANOS Women at Graveside 142 1963 RENt BURRI Ernesto .Che' Guevara 146 1964 LEONARD FREED Martin Luther King 152 1964 DAVID HURN The Beatles 158 1965 DAVID HURN Jean Straker 162 1966 THOMAS HOEPKER Muhammad Ali 166 1967 PHILIP JONES GRIFFITHS Civilian Victim, Vietnam BRIGITTE LARDINOIS 170 1968 BRUNO BARBEY Paris Riots 172 1968 PAUL FUSCO Robert Kennedy Funeral Train 178 1968 JOSEF KOUDELKA Prague Invasion 184 1968 DENNIS STOCK California Rock Concert 190 http://d-nb.info/1051337445 1968 DENNIS STOCK Playa del Rey.
  • Keys Fine Art Auctioneers 8 Market Place Aylsham Norwich Two Day Book and Ephemera Sale Norfolk NR11 6EH Started 27 Mar 2014 10:00 GMT United Kingdom

    Keys Fine Art Auctioneers 8 Market Place Aylsham Norwich Two Day Book and Ephemera Sale Norfolk NR11 6EH Started 27 Mar 2014 10:00 GMT United Kingdom

    Keys Fine Art Auctioneers 8 Market Place Aylsham Norwich Two Day Book and Ephemera Sale Norfolk NR11 6EH Started 27 Mar 2014 10:00 GMT United Kingdom Lot Description 1 Hand Painted “Flower Fairies” Ceramic Plaque, in the style of Cicely Mary Barker, approx 16” x 12”, gt frame 2 A Packet: eight Cicely Mary Barker col’d “Flower Fairy” Prints (8) 3 Kay Nielsen, col’d Print “La Barbe Bleue” circa 1913, approx 12 ½” x 9 ½”, f/g JOHN BRYMER: TWO MERRY MARINERS, ill Stewart Orr, Blackie [1902], 1st edn, 24 col’d plts, obl, 4to, orig cl bkd pict bds worn + 4 EDITH FARMILOE: ALL THE WORLD OVER, 1898, 1st edn, 30 col’d plts, obl, 4to, orig cl bkd pict bds worn, inner jnt weak + [BRENDA GIRVIN]: GOOD QUEEN BESS, ill Jo ...[more] JOHN RONALD REUEL TOLKIEN, 5 ttls: THE SILMARILLION, 1977, 1st edn, orig cl, d/w; UNFINISHED TALES, 1980, 1st edn, orig cl, 5 d/w; THE BOOK OF LOST TALES, 1984-88, 4th impress, vols 1-2, orig cl, d/ws; THE LETTERS OF, 1981, 1st edn, orig cl, d/w; THE CHILDREN OF HURIN, 2007, 2nd printing, orig cl, d/w ...[more] JOHN RONALD REUEL TOLKIEN: THE LORD OF THE RINGS, 1956-58, 1st edn, 5th impress, 5th impress, 4th impress, 3 vols, orig cl, 6 vols 2 and 3 d/ws (3) 7 RICHARD ADAMS: WATERSHIP DOWN, L, Rex Collings, 1972, 1st edn, orig cl gt, d/w 8 KENNETH GRAHAME: THE WIND IN THE WILLOWS, 1908, 1st edn, frontis by Graham Robertson, orig pict cl gt, a little rubbed, teg 9 ELINOR MAY BRENT-DYER: TWO SAMS AT THE CHALET SCHOOL, 1967, 1st edn, orig cl, d/w ELINOR MAY BRENT-DYER, (2 ttls): A LEADER IN THE CHALET SCHOOL, 1961, 1st edn, orig
  • Download .PDF

    Download .PDF

    Yale university press Fall/Winter 2020 Marcus Carey Batchelor Bate Under the Red White A Little History of The Art of Solitude Radical Wordsworth and Blue Poetry Hardcover Hardcover Hardcover Hardcover 978-0-300-25093-0 978-0-300-16964-5 978-0-300-22890-8 978-0-300-23222-6 $23.00 $35.00 $26.00 $25.00 Unwin/Tipling Delbanco Leibovitz Campbell Flights of Passage Why Writing Matters Stan Lee Year of Peril Hardcover Hardcover Hardcover Hardcover 978-0-300-24744-2 978-0-300-24597-4 978-0-300-23034-5 978-0-300-23378-0 $40.00 $26.00 $26.00 $30.00 Van Engen Reynolds Taylor Musonius Rufus City on a Hill Allah Sons of the Waves That One Should Hardcover Hardcover Hardcover Disdain Hardships 978-0-300-22975-2 978-0-300-24658-2 978-0-300-24571-4 Hardcover $30.00 $30.00 $30.00 978-0-300-22603-4 $22.00 RECENT GENERAL INTEREST HIGHLIGHTS Yale university press FALL/WINTER 2020 GENERAL INTEREST 01 JEWISH LIVES® 24 MARGELLOS WORLD REPUBLIC OF LETTERS 26 SCHOLARLY AND ACADEMIC 56 PAPERBACK REPRINTS 73 ART + ARCHITECTURE A 1 front cover illustration: Via Roma, Genoa, Italy, ca. 1895. From Stories for the Years, page 28 “This book is superb, utterly FROM TAKE ARMS AGAINST A SEA OF TROUBLES: convincing, and absolutely invigorating. Bloom’s final argument with mortality What you read and how deeply you read matters almost as much as how you ultimately has a rejuvenating love, work, exercise, vote, practice charity, strive for social justice, cultivate effect upon the reader, kindness and courtesy, worship if you are capable of worship.
  • Download Issue

    Download Issue

    'i: 911 i" Virtual History An Intimate ALTERNATIVESAND COUNTERFACTUALS History of Killing EDITZBBY NIALL FERGUSON FACETO FACEKILLING IN 2OTHCENTURY WARFARE JOANNA BOORKE I~~~Bc~-:~i::: i::::;:: i:: i:: : - ;- :: : : - ;:i --- I'---a~E_ ~~:History des9~~1- I~by~eYeryhist0rian..,:!' team of historians~~ ~~fO'c~· venre asenes a~ "' IIIJLIIUIUe~~,mi*l·nlnml ce~ury:turningpeints.8 ~un~. -a·--PC~~n~·:nn~,,,l, : nsih, Tnlnnmnb ~~"l":"LUR""I:nl'uI rlr, Y,,, lli1~61L1~11 a or:nusslas:war - Duel The Sword and ALEXANDERHAMILTON, AARON BURR the Shield ANDTHE FUTUREOF AMERICA THE MITROKHINARCHIVE AND THOMASFLEMING THESECRET HISTORY OFTHE KGB CHRISTOPHER ANDREW AND VASILI MITROKHIN THOMAS FLEMINGI :::·j~:-~~ ---··-·-- ····-: ···~: ···~~-·I ~~~:·-·~·-· I c ~"~'` "e~ ,revea~lnD· andrelevant...it remindf~ men:~power;and P~~~ ~~Sed humanrl,;,:,~~~ --~~~~~mTade~lPilitrakhin·the KGB:asu,- ~P[aCe-I'~KennethT.Jacksonl·IU··`l:l~~ _ ~rjppe~~~ i~ Histbry:andSocial Sciencesl -I:~,=_S--L~lhP~~~k Review :=i:::- -VYIUI"U'PUIIIIIIIIV a ~A~IONA~BES~'ELLER~-~ 5~1n,ll ~a~p~~f~~ 1 I g ~ I a;~ ss1CI1I Igs 8 Some~p~o~l~ithink :Mexico City was the ii0ngestj Mmp!:)lI,ever,:'made.l BUtJ Ust i: gett ing Ithe~:~as toug her. As a kid, I Was~in:~::gang.·. in trouble With:the:law. ifnot ior a c~i:id~n·5:c0~iud9k Who saw more in:me:'-'who knew that when kids are supported by caring adults, they can learn from their mistakes - I could have landed in prison. He sent me to an alternative school where people helped me get on track. k The children's court gave me the chance to land on:my feet.
  • Luganophotodays Brochure

    Luganophotodays Brochure

    LuganoPhotoDays 13-18 novembre 2012 LuganoPhotoDays nasce come primo festival a Lugano (Svizzera) dedicato al mondo I della fotografia. T A L La sua prima edizione avrà luogo dal 13 al 18 novembre del 2012 e sarà suddivisa in I A due workshop durante la giornata (uno da martedì a giovedì e uno da venerdì a N sabato) e di quattro presentazioni aperte al pubblico (talks) la sera. O Talks pubblici Workshop mercoledì, 14 Novembre alle 20:00 13-15 Novembre Antonio Amendola con Alex Majoli su “Shoot 4 Change” sull’importanza della passione per creare un progetto personale giovedì, 15 Novembre alle 20:00 Alex Majoli 16-18 Novembre su “storia della Magnum e con Nikos Economopoulos progetti personali” sul editing (selezione) fotografico venerdì, 16 Novembre alle 20:00 Nikos Economopoulos Contatti sulla sua retrospettiva Marco Cortesi sabato, 17 Novembre alle 20:00 [email protected] Valerio Spada tel. +41 91 220 22 00 su “Gomorrah Girl ed il fax +41 91 220 22 01 self-publishing” www.luganophotodays.ch Le presentazioni sono tenute in italiano. www.facebook.com/LuganoPhotoDays L’ingresso è libero. www.twitter.com/LuganoPhotoDays MAIN SPONSORS TECHNICAL SPONSORS LuganoPhotoDays 13-18 novembre 2012 Alex Majoli I T A Alex Majoli nasce il 1971 a Ravenna (Italia). A 15 anni L entra a far parte dello studio F45, dove inizia a I A lavorare al fianco di Daniele Casadio. N Durante gli studi presso l’Istituto d’Arte di Ravenna O diventa membro dell’Agenzia Grazia Neri e viaggia in Yugoslavia per documentarne i conflitti. Ritornerà diverse volte negli anni seguenti, occupandosi dei maggiori scontri ed eventi di Kosovo e Albania.
  • Book XVIII Prizes and Organizations Editor: Ramon F

    Book XVIII Prizes and Organizations Editor: Ramon F

    8 88 8 88 Organizations 8888on.com 8888 Basic Photography in 180 Days Book XVIII Prizes and Organizations Editor: Ramon F. aeroramon.com Contents 1 Day 1 1 1.1 Group f/64 ............................................... 1 1.1.1 Background .......................................... 2 1.1.2 Formation and participants .................................. 2 1.1.3 Name and purpose ...................................... 4 1.1.4 Manifesto ........................................... 4 1.1.5 Aesthetics ........................................... 5 1.1.6 History ............................................ 5 1.1.7 Notes ............................................. 5 1.1.8 Sources ............................................ 6 1.2 Magnum Photos ............................................ 6 1.2.1 Founding of agency ...................................... 6 1.2.2 Elections of new members .................................. 6 1.2.3 Photographic collection .................................... 8 1.2.4 Graduate Photographers Award ................................ 8 1.2.5 Member list .......................................... 8 1.2.6 Books ............................................. 8 1.2.7 See also ............................................ 9 1.2.8 References .......................................... 9 1.2.9 External links ......................................... 12 1.3 International Center of Photography ................................. 12 1.3.1 History ............................................ 12 1.3.2 School at ICP ........................................
  • Fourth Global Meet on Rhetoric to Begin Today

    Fourth Global Meet on Rhetoric to Begin Today

    MEMBERS OF MOCK FIRE OVER 60 INDIAN DRILLS AT TAKE PART IN FORUM ASHGHAL ASTER BLOOD PLEDGE TO TOWERS, DONATION DONATE MOVENPICK DRIVE IN ORGANS AL RAYYAN PAGE 14 | DATELINE DOHA PAGE 15 | METRO MUSINGS PAGE 15 | METRO MUSINGS Weather Today PRAYER TIMING Fajr: 4:59 am Dhuhr: 11:42 am DUSTY & CLOUDY Asr: 2:43 pm Maghrib: 5:03 pm Sunrise 6:21 am Isha: 6:33 pm Sunset 5:03 pm High 20ºC Low 16ºC Wind 40 kts Visibility moderate Pressure 1013 mb Rel. humidity 40% Friday, January 11, 2013 RECOGNITION OF EXCELLENCE Deputy PM inaugurates HMC patient workshop on Darfur peace care initiative QNA DOHA gets a boost DEPUTY Prime Minister and Minister of State for Cabinet TRIBUNE NEWS NETWORK Director of Medical Affairs HE Ahmed bin DOHA Education and program Abdullah al Mahmoud on leader Dr Abdullatif al Khal Thursday opened a four-day PATIENT care improve- expressed his appreciation workshop on Darfur peace in ment activities led by health- for the support given to the Doha. care teams at Hamad programme by senior corpo- The workshop is being Medical Corporation (HMC) rate leaders, hospital med- organised by the Mediation have received a boost with ical directors, chairpersons Support Team of the United the Clinical Care and heads of clinical depart- Nations-African Union Improvement Training ments. “Quality is a never- Mission in Darfur (UNAMID) Programme (CCITP), which ending journey and we are for Sudan’s Justice and ca help HMC clinicians to grateful for the corporation- Equality Movement (JEM). execute clinical care wide support to our efforts to The delegation of the Minister of Culture, Arts and Heritage HE Dr Hamad bin Abdulaziz al Kuwari presents an award to Qatari artiste Hassan improvement projects.
  • List of Food Samples for Testing of Melamine IO 29.9.2008 V3

    List of Food Samples for Testing of Melamine IO 29.9.2008 V3

    Unsatisfactory results of testing of Melamine 「「「三聚氰胺「三聚氰胺」」」測試不合格的食物樣本」測試不合格的食物樣本 抽驗結果公布日期: 29.9.2008 Serial Sample Melamine Manufacturer’s name & address Photo No. 樣本名稱 Detected 製造商名稱及地址 相片 編號 1 Licheng Milk Slice (Original) 8.3 ppm Manufacturer: 內蒙古利誠實業有限公司 利誠實業干吃奶片(原味) 4.7 ppm Address: 內蒙古呼和浩特市機塲路鴻盛高科技園區緯二 (淨重: 168 克) (法定上限: 路 (Expiry Date: 10.03.2009) 百萬分之2.5 (Expiry date : 13.03.2009) Legal Limit : 2.5 ppm) Satisfactory results of testing of Melamine 「「「三聚氰胺「三聚氰胺」」」測試合格的食物樣本」測試合格的食物樣本 抽驗結果公布日期: 29.9.2008 Serial Sample Manufacturer’s name & address Photo No. 樣本名稱 製造商名稱及地址 相片 編號 1 Meiji Hohoemi Milkpowder Cube (Net Weight: Manufacturer: Meiji Dairies Corporation 108 g) Address: 1-2-10, Shinsuna, Koto-ku, Tokyo (Expiry date : 21.6.2009) 明治乳業株式會社KS 東京都江東區新砂1-2-10 2 Icero Follow Momo Milk Powder Above 9 Month Manufacturer: Icero Co., Ltd. (Net Weight: 900 g) Address: 16-23, Minato 4-Shibaura, Minato-ku, (Expiry date : 14.10.2009) Tokyo, Japan 3 Gerber Graduates Finger Foods Biter Biscuits Manufacturer: Gerber Products Company (Net weight 5 oz (142g)) Address: Fremont, MI 49413, USA (Expiry date : 25.4.2010) Satisfactory results of testing of Melamine 「「「三聚氰胺「三聚氰胺」」」測試合格的食物樣本」測試合格的食物樣本 抽驗結果公布日期: 29.9.2008 Serial Sample Manufacturer’s name & address Photo No. 樣本名稱 製造商名稱及地址 相片 編號 4 Heinz Smooth Strawberry Yoghurt Dessert (110g Manufacturer: H.J. Heinz Company Australia Limited Net) Address: 105 Camberwell Road, Hawthorn East, Victoria 3123 (All ages from 6 months) Australia (Expiry date : 24.3.2010) 5 Kameda Haihain (Weight 53g) Manufacturer: Kameda Seika Company Limited (Expiry date : 22.12.2008) Address: 3-1-1 Kamedakogyodanch Konan Nigata Nigata, Japan Product of Japan 6 Takara Animal Mate Biscuits (Net Weight 340g) Manufacturer: Takara Confectionery Co., Ltd.
  • English: - "Woof, Woof Dear Lord and Other Stories", [Tr.By]: Leo Marshall, Athens: Kedros, 1995

    English: - "Woof, Woof Dear Lord and Other Stories", [Tr.By]: Leo Marshall, Athens: Kedros, 1995

    0161100008 POLYPHONIC CARAVAN- LETTERS OF CONSENT- LIST I ITH NAMEQE THE I ENTITY LGROUP CAPACITY GENDE 1c~l-JM' I CIH SIGNATORY/RIES REfRESENIED OF THE ROF - IBYTHE SIGNAIQRYL THE LE g[oliPAV) . 201 9 SIGNAIQRY/ lES. SIGNAI N EMBE RIES QRYL IES N · ~-~. ...... ??~ 5 - 1. Nikolaos Arvanitis Non-profit Member of the Male organization Board of Tel: +30 2103310919 "Apiros" (Intemati Directors Website: anal Polyphonic www.polyphonic.gr Song Festival - Facebook site: Polyphonic Polyphonic Caravan, Facebook Caravan) group: POLYPHONIC SONG ' You tube: Polyphonicfestival, A pi 13os - 2. Aliki Gkana, Ourania Polyphonic Group Interpreters of Male (4), Mixed Batsinila, Katerina "Chaonia" the polyphonic Female group Euthimiou, Penny song, Members (8) Spyropoulou, Evi of the Makatsori, Eleni Gerakiti, Polyphonic Christos Diplas, Giorgos Group Diochnos, Giorgos Toutsis, "Chaonia" Daphne Tsiavou, Eugenia Kagianni, I. Alexandros Lambridis Tel: + 30 6973342113 Email: [email protected] Facebook site: CHAONIA polyphonic group 3. Vaggelis Kotsou Polyphonic Group Interpreter of Male Mixed "Polyphonico of the polyphonic groups Tel: + 30 6944446186 Epirus" (V. song, Teacher Email: Kotsou), of Polyphonic yagg!::lis.kQtsmi@gwai].cQm Polyphonic Group and Folk Song, "Pentatono", Musician, Polyphonic Group Member and of the Association Representative "Xenia" of ofthe Kalamata Polyphonic Groups "Polyphonico ofEpirus" (V. ' Kotsou), "Pentatono'', Polyphonic Group ofthe Association "Xenia" of Kalamata -- - - POLYPHONIC CARAVAN – LETTERS OF CONSENT - LIST 4. Kostas Katsavaras
  • Nestlé Waters, to Succeed Him

    Nestlé Waters, to Succeed Him

    Nestlé – Annual Review 2016 Annual Review 2016 WorldReginfo - 8a7d5213-eb65-4648-8062-2f092a53a929 Contents 2 Letter to our shareholders 10 The strategy 14 The highlights 34 150 years 42 Financial review 44 Group overview 48 Product category and operating segment review 55 Principal risks and uncertainties 57 Factories 58 Corporate Governance and Compliance 59 Corporate Governance 60 Board of Directors of Nestlé S.A. 62 Executive Board of Nestlé S.A. 64 Compliance 65 Shareholder information Accompanying reports Nestlé in society Corporate Governance Report 2016 Creating Shared Value and Compensation Report 2016 meeting our commitments 2016 Financial Statements 2016 Nestlé in society Corporate Governance Report 2016 Creating Shared Value Compensation Report 2016 and meeting our Financial Statements 2016 commitments 2016 WorldReginfo - 8a7d5213-eb65-4648-8062-2f092a53a929 Our business For 150 years, Nestlé has created products that enhance quality of life and contribute to a healthier future. Across the globe we provide What we sell (in CHF billion) safe nutritious products for individuals and families. We Powdered and Nutrition and Milk products Prepared dishes Liquid Beverages Health Science and Ice cream and Cooking aids have seven categories in our product portfolio, offering tastier and healthier choices for every life stage, at all 19.8 15.0 14.3 12.1 times of the day. PetCare Confectionery Water 12.1 8.7 7.4 Our continued growth has Where we sell (in CHF billion) enabled us to help improve the lives of millions of people through the products and EMENA services we provide, creating 26.8 value for both our business and the communities where we operate.